An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Symproic

Chemical Namenaldemedine
Dosage FormTablet (oral; 0.2 mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyBioDelivery Sciences International Inc.
Approval Year2017

Indication

  • To treat opioid-induced constipations in adults with chronic non-cancer pain.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Symproic (Naldemedine) Prescribing Information 2017BioDelivery Sciences International, Inc., Raleigh, NC
Document TitleYearSource
Naldemedine for treating opioid-induced constipation.2020NICE
Document TitleYearSource
Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis. 2019Journal of Gastroenterology and Hepatology
Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: Systematic review and network meta-analysis. 2019Gut
Efficacy of treatments for opioid-induced constipation: Systematic review and meta-analysis. 2018Clinical Gastroenterology and Hepatology
Drugs for treating opioid-induced constipation: A mixed treatment comparison network meta-analysis of randomized controlled clinical trials. 2018Journal of Pain and Symptom Management
Document TitleYearSource
American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. 2019Gastroenterology